title: Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Pellegrino
authors.initials: P
authors.lastname: Musto
authors.forename: Marzia
authors.initials: M
authors.lastname: Defina
authors.forename: Fiorella
authors.initials: F
authors.lastname: D'Auria
authors.forename: Giulia
authors.initials: G
authors.lastname: Papini
authors.forename: Teodora
authors.initials: T
authors.lastname: Statuto
authors.forename: Teodora
authors.initials: T
authors.lastname: Steduto
authors.forename: Giovanni
authors.initials: G
authors.lastname: D'Arena
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D000077269:Lenalidomide; D007952:Leukemia, Plasma Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide